Laura Sutcliffe

Bristol-Myers Squibb Co’s (NYSE: BMY) CheckMate 026 trial to evaluate IO drug Opdivo for monotherapy in first-line NSCLC in PD-Li positive patients has ended in failure. Berenberg’s Laura Sutcliffe downgraded the rating on the company from Buy to Hold, while lowering the price...

Bristol-Myers Squibb Co (NYSE: BMY) shares are down 7 percent since December 22. Berenberg’s Laura Sutcliffe upgraded the rating for the company from Hold to Buy, while raising the price target from $74 to $77. The company appears well positioned to generate robust growth in the...